| 1 |
吴国明，钱桂生. 非小细胞肺癌靶向治疗研究进展及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(4): 405-408.
|
| 2 |
Kuburich NA, den Hollander P, Pietz JT, et al. Vimentin and cytokeratin：Good alone, bad together[J]. Semin Cancer Biol, 2022, 86(3): 816-826.
|
| 3 |
Yip TC, Lyu F, Lin H, et al. Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future[J]. Clin Mol Hepatol, 2023, 29(l): 171-183.
|
| 4 |
Li YP, Jia XP, Jiang YQ, et al. Differential expression of cytokeratin 14 and 18 in bladder cancer tumorigenesis[J]. Exp Biol Med (Maywood), 2018, 243(4): 344-349.
|
| 5 |
Yang J, Gao S, Xu J, et al. Prognostic value and clinicopathological significance of serum- and tissue-based cytokeratin 18 express level in breast cancer: a meta-analysis[J]. Biosci Rep, 2018, 38(2): BSR20171145.
|
| 6 |
Huang Y, Yang L, Lin Y, et al. Prognostic value of non-invasive serum Cytokeratin 18 detection in gastrointestinal cancer: a meta-analysis[J]. J Cancer, 2019, 10(20): 4814-4823.
|
| 7 |
Zhang B, Wang J, Liu W, et al. Cytokeratin 18 knockdown decreases cell migration and increases chemosensitivity in non-small cell lung cancer[J]. J Cancer Res Clin Oncol, 2016, 142(12): 2479-2487.
|
| 8 |
Liu Q, Qiao M, Lohinai Z, et al. CCL19 associates with lymph node metastasis and inferior prognosis in patients with small cell lung cancer[J]. Lung Cancer, 2021, 162: 194-202.
|
| 9 |
周 宇. 肺癌患者癌组织中SHIP2、PLEK2蛋白表达水平及其临床预后意义[J]. 实用癌症杂志，2022, 38(2): 187-191.
|
| 10 |
Saikawa H, Nagashima H, Cho K, et al. Relationship between Trace Element in Tumor and Prognosis in Lung Cancer Patients[J]. Medicina (Kaunas), 2021, 57(3): 209.
|
| 11 |
Nooreldeen R, Bach H. Current and future fevelopment in lung cancer diagnosis[J]. Int J Mol Sci, 2021, 22(16): 8661.
|
| 12 |
Bade BC, Dela Cruz CS. Lung cancer 2020: Epidemiology, etiology，and prevention[J]. Clin Chest Med, 2020, 41(1): 1-24.
|
| 13 |
王居鹏. 角蛋白18的功能及在肿瘤诊疗中的研究应用[J]. 天津医科大学学报，2022, 28(6): 691-695.
|
| 14 |
Korver S, Bowen J, Pearson K, et al. The application of cytokeratin-18 as a biomarker for drug-induced liver injury[J]. Arch Toxicol, 2021, 95(11): 3435-3448.
|
| 15 |
Lim Y, Ku NO. Revealing the roles of Keratin 8/18-associated signaling proteins involved in the development of hepatocellular carcinoma[J]. Int J Mol Sci, 2021, 22(12): 6401.
|
| 16 |
师锐赞，牛亚楠，高 宇，等. 细胞角蛋白18下调增加非肌肉肌球蛋白ⅡA表达促进乳腺癌转移[J]. 中国药理学通报，2022, 38(6): 861-865.
|
| 17 |
Shi R, Liu L, Wang F, et al. Downregulation of cytokeratin 18 induces cellular partial EMT and stemness through increasing EpCAM expression in breast cancer[J]. Cell Signal, 2020, 76: 109810.
|
| 18 |
Menz A, Weitbrecht T, Gorbokon N, et al. Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors: a tissue microarray study on 11，952 tumors[J]. Mol Med, 2021, 27(1): 16.
|
| 19 |
Singh Bhangu J, Macher-Beer A, Schimek V, et al. Circulating caspase-cleaved cytokeratin 18 correlates with tumour burden and response to therapy in patients with colorectal cancer liver metastasis[J]. Clin Chim Acta, 2023, 538: 53-59.
|
| 20 |
Sirniö P, Väyrynen JP, Mutt SJ, et al. Systemic inflammation is associated with circulating cell death released keratin 18 fragments in colorectal cancer[J]. Oncoimmunology, 2020, 9(1): 1783046.
|
| 21 |
Shi R, Wang C, Fu N, et al. Downregulation of cytokeratin 18 enhances BCRP-mediated multidrug resistance through induction of epithelial-mesenchymal transition and predicts poor prognosis in breast cancer[J]. Oncol Rep, 2019, 41(5): 3015-3026.
|
| 22 |
Hendawy SR, Mansour M, Hamed M, et al. Serum cytokeratin 18 as a potential early marker for chemotherapy response in breast cancer patients: A prospective study[J]. Asian Pac J Cancer Prev, 2023, 24(3): 969-975.
|
| 23 |
Lorente L. New prognostic biomarkers of mortality in patients undergoing liver transplantation for hepatocellular carcinoma[J]. World J Gastroenterol, 2018, 24(37): 4230-4242.
|
| 24 |
López-Sánchez GN, Montalvo-Javé E, Domínguez-Perez M, et al. Hepatic mir-122-3p, mir-140-5p and mir-148b-5p expressions are correlated with cytokeratin-18 serum levels in MAFLD[J]. Ann Hepatol, 2022, 27(6): 100756.
|
| 25 |
Sears CR, Mazzone PJ. Biomarkers in lung cancer[J]. Clin Chest Med, 2020, 41(1): 115-127.
|